WESTFORD, Mass., Jan. 5 /PRNewswire/ -- LightLab Imaging Inc. today announced several important developments in the field this past year that are the culmination of sustained clinical and technology investment by the company. These advances significantly increase the Company's leadership position in intravascular optical coherence tomography, or OCT. OCT is a new high-resolution, high-speed imaging modality that uses advanced photonics for intravascular imaging and tissue characterization. LightLab is using its unique portfolio of highly proprietary technology to design, manufacture and sell intravascular OCT systems that aid interventional cardiologists in the diagnosis and treatment of coronary artery disease.
With a ten-fold higher resolution than intravascular ultrasound, OCT is poised to become the gold standard imaging modality when high resolution images are essential. As of December 31, 2008, Light Lab has more than 300 M2(TM) and M2x(TM) systems in 20 countries in Europe, Asia, the Middle East and South America. Per-system catheter utilization increased 45% in 2008 over 2007, and the number of imaging catheters sold in 2008 increased 90% from 2007 levels. The number of clinical OCT procedures using LightLab Imaging OCT systems has now surpassed 10,000, providing LightLab with unsurpassed "real-world" experience with OCT.
"From all perspectives, LightLab is recognized as the clear global leader
in intravascular OCT," said David Kolstad, LightLab Imaging's President and
CEO. "During 2008, we continued to execute strategies that will further
extend our leadership position in the year ahead. Among them, we expect to
shortly announce the initiation of patient enrollment in a major clinical
study of our intravascular OCT system here in the United States. In addition,
in October we became the only reimbursed intravascular OCT imaging product in
the world when we received a favorable reimbursement
|SOURCE LightLab Imaging|
Copyright©2009 PR Newswire.
All rights reserved